Relmada Therapeutics, Inc. has filed an 8-K form with the SEC, detailing its financial results for the year ended March 19, 2026. The filing includes significant disclosures under Item 2.02, which covers the results of operations and financial condition, as well as Item 7.01 regarding Regulation FD Disclosure. The report indicates that the company is in compliance with regulatory requirements and provides a comprehensive overview of its financial performance. The filing also includes a press release dated March 19, 2026, which outlines a corporate update and highlights key financial metrics. Additionally, the company has provided a corporate presentation that summarizes its strategic outlook and operational execution. The filing is part of Relmada's ongoing commitment to transparency and governance, ensuring that stakeholders are informed about the company's financial health and strategic direction. The documents submitted include various graphics and data files that support the financial disclosures made in the 8-K. Investors and analysts will be keen to review these documents to assess the company's performance and future prospects.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.